ROS Focused Partnerships BioLum's highly sensitive chemiluminescent assays targeting reactive oxygen, nitrogen, and sulfur species offer superior signal-to-noise compared with traditional methods, aligning with pharma R&D for biomarker analysis, target identification, and early mechanism-of-action studies. These capabilities support collaborative preclinical discovery and compound screening programs.

HTS Ready Capabilities The assays are designed for high-throughput screening with clinical translation, enabling rapid screening of compound libraries, dose-response profiling, and PK/PD insights in early drug discovery. This positions BioLum to accelerate lead identification for pharmaceutical clients seeking robust ROS/RONSS readouts.

Custom Synthesis Repurposing BioLum offers custom assay synthesis, small molecule synthesis, and drug repurposing support, enabling clients to generate bespoke assays for novel targets, validate mechanisms of action, and explore repurposed candidates efficiently.

Strategic Location Relocating to Houston and joining JLABS at TMC places BioLum in a vibrant life sciences hub, improving access to collaborations, incubator resources, and a potential client network in a major pharma ecosystem.

Nitric Oxide Focus BioLum specializes in vascular endogenous nitric oxide monitoring through chemiluminescent assays and has experience with grant-funded programs, providing capabilities to support inflammation, cardiovascular signaling, and related pathways in partnership with research or industry customers.